Immucell Corp
ICCC- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000811641
No open-market purchases or sales by Immucell Corp insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.4M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Immucell Corp insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Immucell Corp, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| te Boekhorst Paul Francis Olivier | President and CEO | 17,785 | Jun 22, 2026 | 4 |
| Tomsche David Scott | Director | 4,740Indirect | Apr 16, 2026 | 3 |
| Wainman Paul R | Director | – | Apr 16, 2026 | 2 |
| Turner Kathy V | Director | – | Apr 16, 2026 | 1 |
| Basse Gloria F | Director | 3,530 | Apr 16, 2026 | 2 |
| Brockmann Bobbi Jo | VP of Sales and Marketing | – | Apr 14, 2026 | 2 |
| Rosgen Steven T. | Director | – | Apr 14, 2026 | 1 |
| Gathagan Bryan K. | Director | 1,000 | Apr 14, 2026 | 1 |
| Brigham Michael F | Director | 205,700 | Mar 24, 2026 | 1 |
| Fiori Timothy C | Chief Financial Officer | – | Jan 29, 2026 | 1 |
| Cunningham David | Director | 16,000 | Jan 24, 2023 | 0 |
| Crabb Joseph H | Former VP and CSO | 142,845 | May 18, 2022 | 0 |
| Williams Elizabeth Luttrell | VP of Manufacturing Operations | – | Feb 9, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 22, 2026 (view filing) | Jun 18 | 4 days | te Boekhorst Paul Francis OlivierPresident and CEO | PPurchaseCommon Stock, par value $.01 per share | +8.00K | $9.50 | +$76.0K | +81.8%17.8K after | |
| Dec 4, 2025 (view filing) | Dec 3-4 | 1 day | te Boekhorst Paul Francis OlivierPresident and CEO | PPurchaseCommon Stock $0.10 par value per share | +6.03K | $5.23 | +$31.5K | +162.6%9.74K after | Amended2 lots |
| Nov 28, 2025 (view filing) | Nov 25 | 3 days | Tomsche David ScottDirector | PPurchaseCommon Stock $0.10 par value per share | +1.63K | $4.76 | +$7.77K | +3.2%52.7K after | |
| Nov 28, 2025 (view filing) | Nov 25 | 3 days | Tomsche David ScottDirector | PPurchaseCommon Stock $0.10 par value per share | +1.63K | $4.77 | +$7.79K | +52.6%4.74K after | |
| Jun 12, 2025 (view filing) | Jun 12 | Same day | Gathagan Bryan K.Director | PPurchaseCommon stock $0.10 per value per share | +1.00K | $6.32 | +$6.32K | New position1.00K after | |
| Jun 14, 2022 (view filing) | Jun 13 | 1 day | Cunningham DavidDirector | PPurchaseCommon stock $0.10 per value per share | +1.00K | $8.00 | +$8.00K | +6.7%16.0K after |